Targeted drugs for lung squamous carcinoma are mainly in two aspects: 1, for a few lung cancers with genetic mutations, targeted drugs such as gefitinib, erlotinib and afatinib can be used, because a few lung squamous carcinomas can also be combined with EGFR mutations, once combined with EGFR mutations, the use of these targeted drugs is still very effective. 2, the use of immune checkpoint inhibitors, at present, immune checkpoint inhibitors are also very important targeted drugs for lung The condition of immune checkpoint inhibitors is for PD-1 and PD-L1 expression greater than or equal to 50%, and immune checkpoint inhibitors can be used alone in the first line.